Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126163 | 1.00 | CYP1A1 (0.48) | CYP1A1CYP1B1NTSR1PTGS2SNCA | |
| SCHEMBL2126271 | 0.79 | SMN1; SMN2 (0.58) | CYP1A1CYP1B1NTSR1PTGS2SNCA | |
| SCHEMBL2126269 | 0.79 | SMN1; SMN2 (0.58) | CYP1A1CYP1B1NTSR1PTGS2SNCA | |
| SCHEMBL6990311 | 0.72 | CES2 (0.64) | CYP1A1CYP1B1NTSR1PTGS2SNCA | |
| SCHEMBL6990314 | 0.72 | CES2 (0.64) | CYP1A1CYP1B1NTSR1PTGS2SNCA | |
| SCHEMBL16453648 | 0.70 | PTGS2 (0.70) | CYP1A1CYP1B1NTSR1PTGS2SNCA | |
| SCHEMBL21651087 | 0.69 | LMNA (0.55) | CYP1A1CYP1B1MAPTCYP3A4MAPK1 | |
| SCHEMBL2126166 | 0.69 | TDP1 (0.35) | PTGS2MAPTSMN1; SMN2TDP1MEN1 | |
| SCHEMBL1322379 | 0.68 | SNCA (0.56) | CYP1A1CYP1B1NTSR1PTGS2SNCA | |
| SCHEMBL1322382 | 0.68 | SNCA (0.56) | CYP1A1CYP1B1NTSR1PTGS2SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443132-B1 | PLATINUM (II) ISOQUINOLINE-PYRIDINE-BENZENE BASED COMPLEXES, PREPARING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DIODES MADE THEREFROM | VERSITECH LTD (CN) | 2018-10-10 | — | — | EP | disclosed |
| EP-2443132-A1 | PLATINUM (II) ISOQUINOLINE-PYRIDINE-BENZENE BASED COMPLEXES, PREPARING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DIODES MADE THEREFROM | Versitech Limited (CN) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010145190-A1 | PLATINUM (II) ISOQUINOLINE-PYRIDINE-BENZENE BASED COMPLEXES, PREPARING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DIODES MADE THEREFROM | THE UNIVERSITY OF HONG KONG (CN) | 2010-12-23 | — | — | WO | disclosed |
| US-20100314994-A1 | Platinum (II) Isoqulinoline-Pyridine-Benzene Based Complexes, Methods for Making Same, and Organic Light-Emitting Diodes Including Such Complexes | VERSITECH LIMITED (CN) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100314994-A1 | Platinum (II) Isoqulinoline-Pyridine-Benzene Based Complexes, Methods for Making Same, and Organic Light-Emitting Diodes Including Such Complexes | OCIAD2, PDCD1LG2, PDCD2L | CYP1A1 1599/4885CYP1B1 961/4885NTSR1 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.